Poxel initiates phase 1b multiple ascending dose trial for NASH drug candidate
This study aims to confirm the predicted relative exposure and dose proportionality of PXL065. PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, targets mitochondrial pyruvate carrier (MPC) inhibition. PXL065 is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.